MetaVia Inc. (MTVA)
| Market Cap | 6.98M -58.8% |
| Revenue (ttm) | n/a |
| Net Income | -15.69M |
| EPS | -3.18 |
| Shares Out | 6.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,097 |
| Open | 1.220 |
| Previous Close | 1.250 |
| Day's Range | 1.060 - 1.240 |
| 52-Week Range | 0.966 - 13.420 |
| Beta | 1.24 |
| Analysts | Buy |
| Price Target | 17.67 (+1,566.98%) |
| Earnings Date | Nov 13, 2026 |
About MTVA
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 rece... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MTVA stock is "Buy." The 12-month stock price target is $17.67, which is an increase of 1,566.98% from the latest price.
News
MetaVia completes last patient visit in Phase 1 part 3A study of DA-1726
MetaVia (MTVA) announced that the last patient has completed the final study visit for its Phase 1 clinical trial evaluating DA-1726, a novel GLP-1 dual-receptor agonist. MetaVia elected to extendā¦
MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks Positive Part 3B Interim Data Presented at Precision Liver Symposium ...
MetaVia reports āpositiveā DA-1726 data at Obesity Week 2026
MetaVia (MTVA) announced positive preclinical data from a head-to-head study comparing DA-1726, a novel GLP-1 /glucagon dual-receptor agonist, with retatrutide, a triple GLP-1R/GIPR/GCGR agonist. The ...
MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeekĀ® 2026
Statistically Significant Increase in Liver and Circulating FGF21 Expression Greater Glucose Lowering and Comparable Weight Loss vs. Retatrutide with Less Reliance on Appetite Suppression MetaVia Prep...
MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Positive DA-1726 16-Week Phase 1 Part 3 Interim Data Support Planned Phase 2 Development in MetALD and ALD Appointed Sarah Browne, M.D., as Chief Medical Officer to Help Lead the Next Stage of Clinica...
MetaVia Quarterly report: Q3 2026
MetaVia has published its Q3 2026 quarterly earnings report on November 13, 2026.
MetaVia Earnings release: Q3 2026
MetaVia released its Q3 2026 earnings on November 13, 2026, summarizing the period's financial results.
MetaVia reports āpositiveā DA-1726 Phase 1 Part 3B interim data
MetaVia (MTVA) announced additional positive data from the previously reported interim analysis of Part 3B of its Phase 1 clinical trial of DA-1726, a novel oxyntomodulin analog targeting both GLP-1ā¦
MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial
Adding to Previously Reported 68.1% Liver Fat Reduction and Strengthening Its Liver Profile for MetALD Additional Phase 1 Part 3B Data Highlight DA-1726's 1.47 mg/dL Placebo-Adjusted Reduction in Uric...
MetaVia Announces Poster Presentation on DA-1726 at ObesityWeekĀ® 2026
CAMBRIDGE, Mass., Nov. 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA),Ā a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract hi...
MetaVia reports āpositiveā DA-1726 Phase 1 Part 3B interim data
MetaVia (MTVA) announced positive interim data from Part 3B of its Phase 1 clinical trial of DA-1726, a novel oxyntomodulin analog targeting both GLP-1 and glucagon receptors. The results, presentedā¦
MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data
DA-1726 Also Demonstrated Statistically Significant 13.5% Placebo-Adjusted Weight Loss and Reduced Mean HbA1c from 5.79% to 5.33% in Participants Without Diabetes No New Gastrointestinal Adverse Event...
MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
CAMBRIDGE, Mass., Oct. 28, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA),Ā a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract h...
MetaVia names Sarah Browne, M.D., as Chief Medical Officer
MetaVia (MTVA) announced the appointment of Sarah Browne, M.D., as Chief Medical Officer, effective October 12. Dr. Browne brings more than 20 years of experience spanning clinical development, regula...
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
Brings Extensive Experience Leading Liver and Metabolic Disease Drug Development Programs, Including MASH, and Successfully Advancing Therapies Through Phase 2 and Into Phase 3 Development Deep Expert...
MetaVia reports results from DA-1726-derived radioactivity study
MetaVia (MTVA) announced results from a preclinical tissue distribution study demonstrating that DA-1726-derived radioactivity is slowly absorbed and extensively distributed throughout the body follow...
MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support for the Differentiated Profile of DA-...
MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726 16-Week Topline Data Expected in the Fourth Quarter of 2026 CAMBRIDGE...
MetaVia Earnings release: Q2 2026
MetaVia released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
MetaVia Quarterly report: Q2 2026
MetaVia has published its Q2 2026 quarterly earnings report on August 6, 2026.
MetaVia Slides: Investor presentation
MetaVia has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
MetaVia announces completion of dose titration in Phase 1 study of DA-1726
MetaVia (MTVA) announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed dose titration andā¦
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg Topline Data Remains on Track for Fourth Quarter 2026 CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ ...
MetaVia Transcript: Life Sciences Virtual Investor Forum
The company is advancing dual-action therapies for obesity and MASH, with promising early clinical results and a focus on strategic partnerships. Key data readouts and regulatory milestones are expected by year-end, positioning the firm for significant growth in competitive cardiometabolic markets.
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
CAMBRIDGE, Mass., June 17, 2026 /PRNewswire/ --Ā MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Ki...